Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts

Smita K. Nair, David Snyder, Barry T. Rouse, Eli Gilboa

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

Vaccination with tumor extracts circumvents the need to identify specific tumor rejection antigens and extends the use of active immunotherapy to the vast majority of cancers, in which specific tumor antigens have not yet been identified. In this study we examined the efficacy of tumor vaccines comprised of unfractionated tumor material presented by professional antigen-presenting cells (APC): dendritic cells (DC) or macrophages (M∅). To enhance the relevance of these studies for human patients we used 2 poorly immunogenic murine tumor models and evaluated the effectiveness of the vaccination protocols in tumor-bearing animals. APC (in particular DC) pulsed with unfractionated extracts from these 'poorly immunogenic' tumors were highly effective in eliciting tumor-specific cytotoxic T lymphocytes. A measurable CTL response could be detected after even a single immunization with tumor extract-pulsed DC. DC or M∅ pulsed with tumor extract were also effective vaccines in tumor-bearing animals. In the murine bladder tumor (MBT-2) model a modest extension of survival and 40% cure rate was seen in the animal groups immunized with DC or M∅ pulsed with MBT-2 tumor extract. DC or M∅ pulsed with B 16/F10.9 tumor extract were also remarkably effective in the B 16 melanoma lung metastasis model, as shown by the observation that treatment with APC caused a significant reduction in lung metastases. Cumulatively, the CTL and immunotherapy data from the two murine tumor systems suggest that APC (in particular DC) pulsed with unfractionated cell extracts as a source of tumor antigen may be equally or more effective than genetically modified tumor vaccines.

Original languageEnglish
Pages (from-to)706-715
Number of pages10
JournalInternational Journal of Cancer
Volume70
Issue number6
DOIs
StatePublished - Apr 23 1997
Externally publishedYes

Fingerprint

Antigen-Presenting Cells
Dendritic Cells
Neoplasms
Cancer Vaccines
Neoplasm Antigens
Vaccination
Neoplasm Metastasis
Active Immunotherapy
Lung
Cytotoxic T-Lymphocytes
Cell Extracts
Urinary Bladder Neoplasms
Immunotherapy
Melanoma
Immunization
Macrophages

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. / Nair, Smita K.; Snyder, David; Rouse, Barry T.; Gilboa, Eli.

In: International Journal of Cancer, Vol. 70, No. 6, 23.04.1997, p. 706-715.

Research output: Contribution to journalArticle

@article{ca533732f430453a8d1d4450ceefaf59,
title = "Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts",
abstract = "Vaccination with tumor extracts circumvents the need to identify specific tumor rejection antigens and extends the use of active immunotherapy to the vast majority of cancers, in which specific tumor antigens have not yet been identified. In this study we examined the efficacy of tumor vaccines comprised of unfractionated tumor material presented by professional antigen-presenting cells (APC): dendritic cells (DC) or macrophages (M∅). To enhance the relevance of these studies for human patients we used 2 poorly immunogenic murine tumor models and evaluated the effectiveness of the vaccination protocols in tumor-bearing animals. APC (in particular DC) pulsed with unfractionated extracts from these 'poorly immunogenic' tumors were highly effective in eliciting tumor-specific cytotoxic T lymphocytes. A measurable CTL response could be detected after even a single immunization with tumor extract-pulsed DC. DC or M∅ pulsed with tumor extract were also effective vaccines in tumor-bearing animals. In the murine bladder tumor (MBT-2) model a modest extension of survival and 40{\%} cure rate was seen in the animal groups immunized with DC or M∅ pulsed with MBT-2 tumor extract. DC or M∅ pulsed with B 16/F10.9 tumor extract were also remarkably effective in the B 16 melanoma lung metastasis model, as shown by the observation that treatment with APC caused a significant reduction in lung metastases. Cumulatively, the CTL and immunotherapy data from the two murine tumor systems suggest that APC (in particular DC) pulsed with unfractionated cell extracts as a source of tumor antigen may be equally or more effective than genetically modified tumor vaccines.",
author = "Nair, {Smita K.} and David Snyder and Rouse, {Barry T.} and Eli Gilboa",
year = "1997",
month = "4",
day = "23",
doi = "10.1002/(SICI)1097-0215(19970317)70:6<706::AID-IJC13>3.0.CO;2-7",
language = "English",
volume = "70",
pages = "706--715",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts

AU - Nair, Smita K.

AU - Snyder, David

AU - Rouse, Barry T.

AU - Gilboa, Eli

PY - 1997/4/23

Y1 - 1997/4/23

N2 - Vaccination with tumor extracts circumvents the need to identify specific tumor rejection antigens and extends the use of active immunotherapy to the vast majority of cancers, in which specific tumor antigens have not yet been identified. In this study we examined the efficacy of tumor vaccines comprised of unfractionated tumor material presented by professional antigen-presenting cells (APC): dendritic cells (DC) or macrophages (M∅). To enhance the relevance of these studies for human patients we used 2 poorly immunogenic murine tumor models and evaluated the effectiveness of the vaccination protocols in tumor-bearing animals. APC (in particular DC) pulsed with unfractionated extracts from these 'poorly immunogenic' tumors were highly effective in eliciting tumor-specific cytotoxic T lymphocytes. A measurable CTL response could be detected after even a single immunization with tumor extract-pulsed DC. DC or M∅ pulsed with tumor extract were also effective vaccines in tumor-bearing animals. In the murine bladder tumor (MBT-2) model a modest extension of survival and 40% cure rate was seen in the animal groups immunized with DC or M∅ pulsed with MBT-2 tumor extract. DC or M∅ pulsed with B 16/F10.9 tumor extract were also remarkably effective in the B 16 melanoma lung metastasis model, as shown by the observation that treatment with APC caused a significant reduction in lung metastases. Cumulatively, the CTL and immunotherapy data from the two murine tumor systems suggest that APC (in particular DC) pulsed with unfractionated cell extracts as a source of tumor antigen may be equally or more effective than genetically modified tumor vaccines.

AB - Vaccination with tumor extracts circumvents the need to identify specific tumor rejection antigens and extends the use of active immunotherapy to the vast majority of cancers, in which specific tumor antigens have not yet been identified. In this study we examined the efficacy of tumor vaccines comprised of unfractionated tumor material presented by professional antigen-presenting cells (APC): dendritic cells (DC) or macrophages (M∅). To enhance the relevance of these studies for human patients we used 2 poorly immunogenic murine tumor models and evaluated the effectiveness of the vaccination protocols in tumor-bearing animals. APC (in particular DC) pulsed with unfractionated extracts from these 'poorly immunogenic' tumors were highly effective in eliciting tumor-specific cytotoxic T lymphocytes. A measurable CTL response could be detected after even a single immunization with tumor extract-pulsed DC. DC or M∅ pulsed with tumor extract were also effective vaccines in tumor-bearing animals. In the murine bladder tumor (MBT-2) model a modest extension of survival and 40% cure rate was seen in the animal groups immunized with DC or M∅ pulsed with MBT-2 tumor extract. DC or M∅ pulsed with B 16/F10.9 tumor extract were also remarkably effective in the B 16 melanoma lung metastasis model, as shown by the observation that treatment with APC caused a significant reduction in lung metastases. Cumulatively, the CTL and immunotherapy data from the two murine tumor systems suggest that APC (in particular DC) pulsed with unfractionated cell extracts as a source of tumor antigen may be equally or more effective than genetically modified tumor vaccines.

UR - http://www.scopus.com/inward/record.url?scp=0030966684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030966684&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19970317)70:6<706::AID-IJC13>3.0.CO;2-7

DO - 10.1002/(SICI)1097-0215(19970317)70:6<706::AID-IJC13>3.0.CO;2-7

M3 - Article

C2 - 9096653

AN - SCOPUS:0030966684

VL - 70

SP - 706

EP - 715

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -